Abstract

Invariant natural killer T (iNKT) cells are lipid‐specific T lymphocytes endowed with cytotoxic activities and are thus considered important in antitumor immunity. While several studies have demonstrated iNKT cell cytotoxicity against different tumors, very little is known about their cell‐killing activities in human colorectal cancer (CRC). Our aim was to assess whether human iNKT cells are cytotoxic against colon cancer cells and the mechanisms underlying this activity. For this purpose, we generated stable iNKT cell lines from peripheral blood and colon specimens and used NK‐92 and peripheral blood natural killer cells as cell‐mediated cytotoxicity controls. In vitro cytotoxicity was assessed using a panel of well‐characterized human CRC cell lines, and the cellular requirements for iNKT cell cytotoxic functions were evaluated. We demonstrated that both intestinal and circulating iNKT cells were cytotoxic against the entire panel of CRC lines, as well as against freshly isolated patient‐derived colonic epithelial cancer cells. Perforin and/or granzyme inhibition impaired iNKT cell cytotoxicity, whereas T‐cell receptor (TCR) signaling was a less stringent requirement for efficient killing. This study is the first evidence of tissue‐derived iNKT cell cytotoxic activity in humans, as it shows that iNKT cells depend on the perforin–granzyme pathway and both adaptive and innate signal recognition for proper elimination of colon cancer cells.

Highlights

  • Colorectal cancer (CRC) is the third-most common cancer worldwide and the fourth cancer type for mortality [1]

  • Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies Invariant natural killer T (iNKT) cells kill CRC cells via perforin–granzyme

  • Circulating (PB1, PB2, PB3, PB5, and PB6) and intestinal (CD1, CD2, CD3, and NUN) iNKT cells were coincubated with five colorectal cancer cell lines at different effector : target ratios for in vitro cytotoxicity evaluation by measuring lactate dehydrogenase release (Fig 1A)

Read more

Summary

Introduction

Colorectal cancer (CRC) is the third-most common cancer worldwide and the fourth cancer type for mortality [1]. Chemotherapy, and radiotherapy are currently the most frequently used therapeutic approaches for metastatic and nonmetastatic diseases. Targeted therapies with monoclonal antibodies directed against growth and angiogenic factors have been effectively included in the therapeutic options for CRC patients [1]. Abbreviations CD1d, cluster of differentiation 1d; CRC, colorectal cancer; iNKT, invariant natural killer T cells; LPMC, lamina propria mononuclear cells; NK, natural killer cells; PBMC, peripheral blood mononuclear cells; TCR, T-cell receptor. Molecular Oncology (2021) a 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call